XBI240726P88500
- 0.04
- 0.000.00%
SPDR S&P Biotech ETF Newsroom
AbbVie Says Canada's Drug Agency Has Issued Its First-Ever Time-limited Reimbursement Recommendation For EPKINLY (Epcoritamab)
Here's How Much $1000 Invested In United Therapeutics 5 Years Ago Would Be Worth Today
Cerevel Therapeutics Gains as Investors Appear More Confident on FTC Approval for AbbVie
$100 Invested In This Stock 15 Years Ago Would Be Worth $5,100 Today
AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst
Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst
A Glimpse Into The Expert Outlook On Biomarin Pharmaceutical Through 10 Analysts
Breaking Down Gilead Sciences: 10 Analysts Share Their Views
Regeneron Pharmaceuticals Analyst Ratings
Gilead Sciences Analyst Ratings
Biomarin Pharmaceutical Analyst Ratings
Alnylam Pharmaceuticals Analyst Ratings
Kamala Harris' Potential Impact on Health Care Stocks
Here Are Big Pharma's Leading Blockbuster Makers
What to Expect in the Week Ahead (Google and Tesla Earnings; GDP and PCE Data)
Financials Dominate in Q2 as Wall Street Slides Amidst Concerns on Tech - Earnings Scorecard
Catalyst Watch: Earnings Deluge, Farnborough Airshow, Paris Olympics, and Trump Talks Crypto
Check Out What Whales Are Doing With GILD
Peeling Back The Layers: Exploring AbbVie Through Analyst Insights
Peering Into Regeneron Pharmaceuticals's Recent Short Interest